Edition:
United States

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

5.48USD
27 Sep 2016
Change (% chg)

-- (--)
Prev Close
$5.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
487,857
52-wk High
$14.93
52-wk Low
$4.45

ZIOP.OQ

Chart for ZIOP.OQ

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company's... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $721.89
Shares Outstanding(Mil.): 131.73
Dividend: --
Yield (%): --

Financials

  ZIOP.OQ Industry Sector
P/E (TTM): -- 42.41 36.20
EPS (TTM): -1.31 -- --
ROI: -153.31 -0.33 13.87
ROE: -584.64 -3.14 14.78

Cancer patient dies after Ziopharm experimental drug therapy

Ziopharm Oncology Inc said a brain cancer patient died of cranial bleeding about two weeks after starting treatment with the gene therapy developer's lead experimental drug, sending its stock down as much as 16 percent on Friday.

Jul 15 2016

UPDATE 1-Cancer patient dies after Ziopharm experimental drug therapy

July 15 Ziopharm Oncology Inc said a brain cancer patient died of cranial bleeding about two weeks after starting treatment with the gene therapy developer's lead experimental drug, sending its stock down as much as 16 percent on Friday.

Jul 15 2016

BRIEF-Ziopharm Oncology updates on early study for brain cancer drug

* Ziopharm issues statement regarding phase 1 study of gene therapy candidate ad-RTS-hIL-12 in brain cancer

Jul 15 2016

Cancer patient in Ziopharm drug trial dies after starting treatment

July 15 A brain cancer patient enrolled in Ziopharm Oncology Inc's trial has suffered a fatal cranial bleed a fortnight after starting treatment with the gene therapy developer's lead experimental drug, according to a regulatory filing.

Jul 15 2016

BRIEF-Ziopharm plans for Phase I clinical trial with CD33 CAR-T cell therapy targeting acute myeloid leukemia

* Ziopharm announces plans for Phase I clinical trial with CD33 car-t cell therapy targeting acute myeloid leukemia

Jul 12 2016

BRIEF-Intrexon and Ziopharm amend exclusive channel collaborations

* Intrexon and Ziopharm amend exclusive channel collaborations to improve alignment as programs advance through development

Jun 30 2016

BRIEF-Ziopharm Oncology Q1 loss per share $0.09

* Quarter 2016 financial results and provides update on recent activities

May 10 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.